Core Viewpoint - China Galaxy (06881) has successfully completed the issuance of its second phase of short-term financing bonds for the year 2026, raising a total of RMB 5 billion [1] Group 1 - The issuance scale of the bonds is RMB 5 billion, with a face value and issuance price of RMB 100 per unit [1] - The bonds have a maturity period of 247 days and a final coupon rate of 1.71% [1] - The funds raised from this bond issuance will be used to supplement the company's working capital [1]

格隆汇1月14日丨中国银河(06881.HK)发布公告，公司已于2026年1月14日完成2026年度第二期短期融资 券发行。本期融资券的发行规模为人民币50亿元，面值及发行价均为每单位人民币100元。本期融资券 的期限为247天，最终票面利率为1.71%。本期融资券发行所募集的资金将用于补充公司流动资金。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致之任何損失承擔任何責任。 （在中華人民共和國註冊成立之股份有限公司） （股份代號：06881） 董事會欣然宣佈，根據上述股東授權，本公司已於2026年1月14日完成2026年度 第二期短期融資券發行（「本期融資券」）。本期融資券的發行規模為人民幣50億 元，面值及發行價均為每單位人民幣100元。本期融資券的期限為247天，最終票 面利率為1.71%。本期融資券發行所募集的資金將用於補充本公司流動資金。 承董事會命 中國銀河證券股份有限公司 公告 2026年度第二期短期融資券發行完畢 茲提述中國銀河證券股份有限公司（「本公司」）日期為2025年1月23日的通函以及 2025年2月17日之公告。 於2025年2月17日召開的2025年第一次臨時股東大會上，本公司通過了股東大會 對本公司董事會（「董事會」）的授權方案的修訂，據此，股東大會授權董事會發行 債務融資工具，發行規模合計不超過本公司最近一期經審計淨資產的350%。 董事長及執 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 责任。 中国银河证券股份有限公司 2026 年度第二期短期融资券已于 2026 年 1 月 14 日发行完毕，相关发行情况如下： | 债券名称 | 中国银河证券股份有限公司 | 2026 | 年度第二期短期融资券 | | --- | --- | --- | --- | | 债券简称 | 26 银河证券 CP002 | 债券流通代码 | 072610005 | | 发行日 | 2026 年 1 月 13 日 | 起息日 | 2026 年 1 月 14 日 | | 到期兑付日 | 2026 年 9 月 18 日 | 期限 | 247 天 | | 计划发行总额 | 50 亿元人民币 | 实际发行总额 | 50 亿元人民币 | | 票面年利率 | 1.71% | 发行价格 | 100 元/百元面值 | 本 期 发 行 短 期 融 资 券 的 相 关 文 件 已 刊 登 在 中 国 货 币 网 （www.chinamoney.com.cn）、上海清算所网站（www.shclearing.c ...

(责任编辑：田云绯) 思科瑞首次公开发行股票的发行费用总额为13,574.34万元（发行费用均为不含税金额），其中，中 国银河证券股份有限公司获得承销及保荐费用10,760.38万元。 思科瑞2025年9月20日发布关于实施其他风险警示暨停牌的公告。因思科瑞于2025年9月19日收到中 国证监会四川监管局下发的《行政处罚事先告知书》（川证监处罚字【2025】6号）。依据《事先告知 书》载明的内容，根据《上海证券交易所科创板股票上市规则（2025年4月修订)》相关规定，公司股票 将被实施其他风险警示。A股股票简称由"思科瑞"变更为"ST思科瑞"；扩位简称由"思科瑞微电子"变更 为"ST思科瑞微电子"；实施风险警示的起始日：2025年9月23日。 中国经济网北京1月14日讯 ST思科瑞(688053.SH)今日收报48.68元，跌幅4.70%，总市值48.68亿 元。目前该股处于破发状态。 思科瑞于2022年7月8日在上交所科创板上市，公开发行的股票数量为2500.00万股，发行价格为 55.53元/股，保荐人（主承销商）为中国银河证券股份有限公司，保荐代表人为陈召军、姚召五。 思科瑞首次公开发行股票募集资金总额 ...

雷科防务今日跌9.99%，成交额71.27亿元，换手率33.07%，盘后龙虎榜数据显示，深股通专用席位买入 454.21万元并卖出1.01亿元，有1家机构专用席位净卖出8303.51万元。中国银河大连黄河路净卖出2.94亿 元。 ...

Core Viewpoint - Lianchi Hospital Group Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with China Galaxy International as the sole sponsor [1] Group 1: Company Overview - Lianchi Hospital is a boutique specialty medical group with Chinese characteristics, operating 5 hospitals and 1 elderly care institution under a group management structure by September 30, 2025 [1] - The company adheres to a "patient-first" philosophy and implements a "human-centered medical" management model, establishing the well-known "Lianchi Medical" brand [1] Group 2: Unique Medical Services - Lianchi Hospital offers distinctive medical service models, including painless management, enhanced recovery after surgery (ERAS), integrated medical and nursing care, and no-companion nursing [1] - According to Frost & Sullivan data, Lianchi Hospital has become one of the most influential medical groups in China [1]

Core Viewpoint - The passenger car market in December shows significant divergence, with the implementation of the 2026 vehicle trade-in policy expected to benefit the mid-to-high-end market segment [1][3] Market Performance - In December, retail sales of passenger cars reached 2.261 million units, down 14.0% year-on-year but up 1.6% month-on-month; wholesale sales were 2.789 million units, down 9.0% year-on-year and down 7.0% month-on-month [2] - The overall industry inventory decreased by 60,000 units in December, indicating cautious market conditions prompting dealers to actively reduce inventory [2] - The retail penetration rate for new energy vehicles (NEVs) reached 59.1%, up 9.6 percentage points year-on-year, while the wholesale penetration rate was 56.0%, up 6.6 percentage points year-on-year [2] Policy Impact - The 2026 vehicle trade-in policy introduces a proportional subsidy that favors the 150,000 to 200,000 price segment, which is expected to improve the sales structure of new vehicles [3] - The new policy will provide subsidies of 12% (up to 20,000 yuan) for NEVs and 8% (up to 15,000 yuan) for fuel vehicles, with the overall funding for the 2026 policy set at 625 billion yuan, a reduction compared to the previous year's 3 trillion yuan [3] Future Outlook - The consumer purchasing sentiment is expected to stabilize in January 2026 due to the early implementation of the trade-in policy and the backlog of year-end orders [4] - The market is anticipated to experience a smooth transition in sales as the new policy is expected to mitigate price wars and internal competition [4] Sector Performance - In the recent bi-weekly review, the performance of various sectors showed increases, with parts (+7.24%), commercial vehicles (+2.80%), and passenger vehicles (+2.08%) leading the gains [5] - Valuation metrics indicate that the price-to-earnings ratios for sales and services, parts, motorcycles, passenger vehicles, and commercial vehicles are 36.18x, 33.83x, 26.73x, 22.74x, and 16.73x respectively [5]

Company Overview - Lianchi Hospital has submitted a listing application to the Hong Kong Stock Exchange, with China Galaxy International as the exclusive sponsor [1] - The company is positioned as a high-quality specialty medical group with a focus on patient-centered care and innovative medical service models [1] - By September 30, 2025, the company plans to operate 5 hospitals and 1 elderly care facility, with a total building area of approximately 117,900 square meters and 786 registered beds [1] Operational Performance - As of September 30, 2025, the company has a medical team consisting of 341 practicing physicians and assistant doctors [1] - The outpatient visits, inpatient admissions, orthopedic surgeries, and childbirths are expected to maintain a high level through 2023, 2024, and the first nine months of 2025 [1] - According to Frost & Sullivan, Lianchi Orthopedic Hospital ranks first in Shandong Province and third nationwide in terms of private hospital knee surgery volume for 2024 [1] Industry Trends - The Chinese healthcare service market is experiencing overall growth, with the private hospital sector being one of the fastest-growing components [2] - Revenue from private hospitals increased from RMB 437.9 billion in 2019 to RMB 689.2 billion in 2023, reflecting a compound annual growth rate (CAGR) of 12.0% [2] - It is projected that the revenue for private hospitals will reach RMB 1.88 trillion by 2030, with a CAGR of 12.2% from 2024 to 2030 [2]

Core Viewpoint - China Galaxy Securities has received approval from the China Securities Regulatory Commission (CSRC) to publicly issue corporate bonds totaling up to 30 billion yuan to professional investors [1]. Group 1 - The company has been granted a registration approval for the issuance of corporate bonds with a total face value not exceeding 30 billion yuan [1]. - The approval from CSRC is valid for 24 months from the date of consent, allowing the company to issue the bonds in multiple tranches during this period [1]. - The company will comply with relevant laws, regulations, and the requirements of the approval, and will fulfill its information disclosure obligations in a timely manner [1].